<DOC>
	<DOCNO>NCT01866592</DOCNO>
	<brief_summary>VIP-E one-arm , open-label , 40-52 week extension study continue cross subject VIP study ( # 814278 ) active drug ( adalimumab ) determine sustain improvement vascular inflammation , lipid metabolism , inflammatory marker . VIP-E extends VIP study procedure 40-52 week include questionnaire , physical exam , blood urine sample , lab test , one additional FDG-PET/CT scan , adalimumab injection follow FDA-approved psoriasis treatment regimen .</brief_summary>
	<brief_title>Vascular Inflammation Psoriasis - Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Males females 18 year age old . 2 . Subject complete 12week VIP Study 3 . Subject willing able avoid prolong exposure skin affect psoriasis natural sunlight tan bed course study 4 . Subject willing able avoid topical systemic prescription treatment psoriasis besides adalimumab course study 5 . Women eligible participate study meet one follow criterion : 1 . Women childbearing potential willing undergo regular pregnancy test agree use one method contraception throughout study eligible participate 2 . Women postmenopausal ( least one year ) , sterile , hysterectomized eligible participate 3 . Women undergone tubal ligation eligible participate 4 . Women agree sexually abstinent , defined total abstinence sexual intercourse , form contraception eligible participate study . 6 . Subject judge good general health determine Principal Investigator base upon result medical history , laboratory profile , physical examination . 7 . Able willing give write informed consent comply requirement study protocol . 1 . Previous adverse event follow exposure TNFalpha antagonist lead discontinuation TNF inhibitor contraindicate future treatment . 2 . Previous lack response TNFalpha antagonist lead discontinuation . 3 . Diagnosis erythrodermic psoriasis , generalize pustular psoriasis , medicationinduced medicationexacerbated psoriasis . 4 . Diagnosis active skin disease skin infection ( bacterial , fungal , viral ) may interfere evaluation psoriasis . 5 . Subject take require oral injectable corticosteroid study . Inhaled corticosteroid stable medical condition allow . 6 . Poorly control medical condition , unstable ischemic heart disease , congestive heart failure , recent cerebrovascular accident , psychiatric disease require frequent hospitalization , condition , , opinion Investigator , would put subject risk participation study . 7 . History diabetes mellitus , type 1 type 2 ( patient type 2 diabetes may enrol duration diabetes &lt; 10 year HbA1c &lt; 7.0 % ) 8 . Uncontrolled hypertension , measure systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 90 mmHg 9 . History demyelinate disease lupus . 10 . Subject infection risk factor severe infection , example : Known history HIV , hepatitis B C , severe , recurrent , persistent infection ; Excessive immunosuppression factor associate , include human immunodeficiency virus infection ; Active tuberculosis ( TB ) disease ; Evidence latent TB infection demonstrate Purified Protein Derivative ( PPD ) ≥ 5 mm induration positive QuantiferonGOLD result determine within 6 month baseline visit VIPE ; except prophylactic treatment TB , recommend local guideline , initiate prior administration study drug documentation subject receive prophylactic treatment TB previously . Any significant infection require hospitalization intravenous ( IV ) antibiotic month prior Baseline ; Infection require treatment oral parenteral antibiotic within 14 day prior Baseline ; Subject require live vaccination study participation include 30 day last dose study drug . 11 . Subject history hematological solid malignancy within past five year successfully treat basal cell carcinoma , nonmetastatic cutaneous squamous cell carcinoma cervical carcinoma situ . 12 . Female subject pregnant breastfeeding consider become pregnant study . 13 . Clinic laboratory analysis show follow abnormal result : Hemoglobin ( Hgb ) &lt; 10 g/dL female &lt; 12 g/dL male ; White blood cell ( WBC ) count &lt; 2.5 x 109/L Subject include WBC count &lt; 2.5 x x 109/L absolute neutrophil count ( ANC ) &gt; 1000 cell / mm3 . WBC count &gt; 15 x 109/L ; Platelet count &lt; 100 x 109/L ; Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2.5 upper limit normal ( ULN ) ; Serum total bilirubin ≥2 mg/dL ( ≥26 µmol/L ) 14 . Recent history substance abuse psychiatric illness could preclude compliance protocol . 15 . If subject cholesterollowering medication ( e.g . statin ) , dose form medication must stable 90 day prior baseline remain stable throughout duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Vascular Inflammation</keyword>
	<keyword>Lipid Biomarkers</keyword>
	<keyword>Metabolic biomarkers</keyword>
	<keyword>FDG-PET/CT</keyword>
</DOC>